SCHEMBL8661673

SCHEMBL8661673

CCOP(=O)(/C=C/c1ccccc1)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.53
NPSR1 Q6W5P4 2/20 0.50
RELA Q04206 1/20 0.46
KCNH2 Q12809 1/20 0.44
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
ADAM17 P78536 1/20 0.43
ADAM9 Q13443 1/20 0.43
AOX1 Q06278 1/20 0.42
POLB P06746 1/20 0.42
ACHE P22303 1/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5002639 1.00 NR1I2 (0.53) NR1I2NPSR1RELAKCNH2MMP1
SCHEMBL20710724 0.89 NR1I2 (0.46) NR1I2NPSR1RELAKCNH2MMP1
SCHEMBL28409779 0.86 MEN1 (0.51) NR1I2RELAMMP1MMP3MMP9
SCHEMBL5936857 0.83 LCK (0.49) NR1I2MMP1MMP9MAOAMAOB
SCHEMBL28412694 0.83 TDP1 (0.43) NR1I2RELAMEN1KMT2AKDM4E
SCHEMBL5667061 0.82 GSK3B (0.53) RELAMAOBNPC1
SCHEMBL10262188 0.82 GSK3B (0.53) RELAMAOBNPC1
SCHEMBL4821198 0.82 NPSR1 (0.36) NR1I2NPSR1RELAKCNH2MMP1
SCHEMBL8922929 0.82 APP (0.39) NR1I2NPSR1CYP1A2CYP3A4LMNA
SCHEMBL8922931 0.82 APP (0.39) NR1I2NPSR1CYP1A2CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9198923-B2 Phosphate management with small molecules Opko Ireland Global Holdings, Ltd. (KY) 2015-12-01 US disclosed
US-9198923-B2 Phosphate management with small molecules Opko Ireland Global Holdings, Ltd. (KY) 2015-12-01 US disclosed
US-20120028926-A1 Phosphate Management with Small Molecules CYTOCHROMA INC. (CA) 2012-02-02 US disclosed
US-20120028926-A1 Phosphate Management with Small Molecules CYTOCHROMA INC. (CA) 2012-02-02 US disclosed
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-07-05 US disclosed
US-5852198-A Wittig reagents and method for preparing α,β-unsaturated phosphonates MEDICHEM RESEARCH, INC. (US) 1998-12-22 US disclosed
WO-1997036909-A1 WITTIG REAGENTS AND METHOD FOR PREPARING α,β-UNSATURATED PHOSPHONATES MEDICHEM RESEARCH, INC. (US) 1997-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts OXER1, OSTC, OXSR1 NR1I2 2168/4885NPSR1 1364/4885RELA 2389/4885
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS NR1I2 3695/4885NPSR1 2464/4885RELA 1886/4885
US-20120028926-A1 Phosphate Management with Small Molecules SLC34A2, PHPT1, SLC34A3 NR1I2 3199/4885NPSR1 2039/4885RELA 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.